ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Session » Epidemiology & Public Health Poster III

Date: Monday, November 18, 2024

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2024

10:30AM-12:30PM
Abstract Number: 1882
30-Day Readmission Among Patients with Rheumatoid Arthritis and Their Independent Predictors: Insights from National Readmission Database
10:30AM-12:30PM
Abstract Number: 1871
A Seropositive RA Polygenic Risk Score Does Not Predict Progression to RA in an ACPA Positive Population
10:30AM-12:30PM
Abstract Number: 1869
Analysis of Short-Term Side Effects Following COVID-19 Vaccination in Pregnancies Complicated by Autoimmune Inflammatory Rheumatic Diseases
10:30AM-12:30PM
Abstract Number: 1888
Anti-Spike Antibodies Protect Against COVID-19 Infection in Immune-Mediated Inflammatory Diseases: Findings from the SUCCEED Study
10:30AM-12:30PM
Abstract Number: 1875
Assessing the PULSAR (Program to Understand the Longterm Outcomes in Spondyloarthritis) Registry for Environmental Determinants of Heath Research
10:30AM-12:30PM
Abstract Number: 1895
Association Between a History of Mental Illness and the Risk of Systemic Autoimmune Rheumatic Diseases: A Nationwide, Population-based Case-control Study
10:30AM-12:30PM
Abstract Number: 1891
Association of Physical Activity Levels on Chronic Opioid Use in Radiographic Axial Spondylitis Patients
10:30AM-12:30PM
Abstract Number: 1876
Automated Case Identification of Patients with End-Stage Renal Disease and Systemic Lupus Erythematosus Using Machine Learning
10:30AM-12:30PM
Abstract Number: 1906
Bayesian Algorithm to Identify Osteoarthritis in Administrative Health Data Without Requiring Chart Review
10:30AM-12:30PM
Abstract Number: 1905
Combining Three Peripheral Biomarkers to Stratify Rheumatoid Arthritis-Associated Interstitial Lung Disease Risk
10:30AM-12:30PM
Abstract Number: 1870
Costs and Healthcare Resource Utilization Associated with Inpatient and Day Hospitalizations of Patients with Lupus and Psychiatric Manifestations in France
10:30AM-12:30PM
Abstract Number: 1881
Cross-State Comparative Assessment of Burden of Rheumatoid Arthritis in the United States and It’s Trend from 1990-2021: A Benchmarking Analysis for the Global Burden of Disease Study 2022
10:30AM-12:30PM
Abstract Number: 1894
Detection of Fibrotic Lung Changes and Bronchiectasis in RA Patients Screened for Lung Cancer with Low-dose CT Chest: Results from a Large Multi-hospital System
10:30AM-12:30PM
Abstract Number: 1900
Dietary Exposures Associated with Incident Spondyloarthritis
10:30AM-12:30PM
Abstract Number: 1892
Early Tumor Necrosis Factor Inhibitor Initiation and Chronic Opioid Use in Individuals with Axial Spondyloarthritis
10:30AM-12:30PM
Abstract Number: 1885
Effect of Physical Activity on Mortality in Rheumatoid Arthritis: A Dose-Response Analysis
10:30AM-12:30PM
Abstract Number: 1890
Emergency Department Visits for Ambulatory Care Sensitive Conditions by Persons with Rheumatoid Arthritis: A Population-Based Study
10:30AM-12:30PM
Abstract Number: 1904
Evaluation of the Economic Burden of Psoriatic Arthritis: Assessment of Direct Costs Using National Administrative Databases at National Level
10:30AM-12:30PM
Abstract Number: 1886
Heterogeneity of VEXAS Syndrome: A Multicenter Case-series of 299 Cases from the French VEXAS Study Group (FRENVEX)
10:30AM-12:30PM
Abstract Number: 1887
High Rates of Cost-Related Medication Non-Adherence Among Younger Patients Receiving Immunosuppression Are Exacerbated by Other Chronic Conditions
10:30AM-12:30PM
Abstract Number: 1893
Hydroxychloroquine Use in Early Pregnancy and Risk of Preterm Delivery in a Californian Cohort of Lupus Pregnancy
10:30AM-12:30PM
Abstract Number: 1898
Hyperuricemia Is Associated with Higher Levels of Fasting Plasma Glucose and Insulin Resistance in Non-diabetic Subjects
10:30AM-12:30PM
Abstract Number: 1903
Impact of Multimorbidity on Targeted Synthetic and Biologic Disease-modifying Antirheumatic Drug (ts/bDMARD) Effectiveness in Patients with Rheumatoid Arthritis: A Two Year Follow-up Study from Mexican Adverse Events Registry BIOADAMEX
10:30AM-12:30PM
Abstract Number: 1902
Ixekizumab for the Treatment of Patients with Spondyloarthritis – Real-world Evidence from the Nationwide Danish Registry, DANBIO
10:30AM-12:30PM
Abstract Number: 1872
Nationwide Analysis of Prosthetic Joint Complications with and Without Inflammatory Arthritis
10:30AM-12:30PM
Abstract Number: 1868
Opioid Prescription Rates in Patients with Radiographic Axial Spondyloarthritis in the US Between 2008-2021: A Joinpoint Regression Analysis
10:30AM-12:30PM
Abstract Number: 1897
People Living with Autoimmune Disease Are at Higher Risk of Suffering from Post-Acute Sequelae of SARS-CoV-2 but Immunization Is Protective
10:30AM-12:30PM
Abstract Number: 1889
Prevalence of Physician-Diagnosed versus Clinically Confirmed Primary Sjögren’s Syndrome (SS) Among Adults in the United States
10:30AM-12:30PM
Abstract Number: 1879
Prevalence of Relapsing Polychondritis in Colombia: Data from the National Health Registry 2018 – 2023
10:30AM-12:30PM
Abstract Number: 1883
Psoriatic Arthritis Flare Incidence, Definitions and Risk Factors: A Systematic Review
10:30AM-12:30PM
Abstract Number: 1873
Race/Ethnicity and Household Income at the County Level Interacts with the Association of Urbanicity and Lupus Nephritis Mortality
10:30AM-12:30PM
Abstract Number: 1899
Recurrent Heart Failure Hospitalization in Rheumatoid Arthritis: A National Veterans Affairs Matched Cohort Study
10:30AM-12:30PM
Abstract Number: 1880
Statewide Burden of Osteoarthritis in India and Its Trend from 1990-2021: A Benchmarking Analysis
10:30AM-12:30PM
Abstract Number: 1878
The Associations Between Gout and Ischemic Colitis Among Hospitalized Patients: A Retrospective Nationwide Analysis
10:30AM-12:30PM
Abstract Number: 1896
The Prevalence, Incidence, Risk Factors and Time to Diagnosis of Behcet’s Syndrome in England: A Retrospective Nested Case Control Study in Clinical Practice Research Datalink and Hospital Episode Statistics
10:30AM-12:30PM
Abstract Number: 1877
Trends in Rheumatoid Arthritis Incidence, Prevalence, DALY and Death Rates (1991-2021) in the United States: A Comprehensive Analysis of State-Level Disparities
10:30AM-12:30PM
Abstract Number: 1874
Validation Analysis of the Expanded Risk Score for Rheumatoid Arthritis in a Multicentre Italian Cohort
10:30AM-12:30PM
Abstract Number: 1901
Venous Thromboembolism Risk Is Consistently Increased in People with Rheumatoid Arthritis Across Different Ages, Sexes and Obesity Status: United Kingdom Population Based Study
10:30AM-12:30PM
Abstract Number: 1884
VIVA QI: Vaccination In Vasculitis: Applying a Quality Improvement Approach

« View all sessions from this meeting

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology